Finally, as an additional validation of ERBB2 as a potential mechanism of resistance to HER3-DXd, we assessed HER2DX ERBB2 in the baseline tumors of a cohort of 30 breast cancer patient-derived xenografts (PDXs) treated with HER3-DXd16. This evidence concerns the gene ERBB3 and breast carcinoma.